drugset / Trial / NCT00004585

A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults

NCT00004585

Phase 4 Completed 40 enrolled Glaxo Wellcome
Treatment

Summary

The purpose of this study is to see if a certain combination of anti-HIV drugs is safe and effective in HIV-infected patients. The drug combination includes a tablet containing lamivudine and zidovudine (called Combivir) plus abacavir plus efavirenz.

Timeline

Start
1999-10
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Abacavir Other / unclassified 300 mg
Subject Efavirenz Other / unclassified 600 mg
Subject Lamivudine Other / unclassified 150 mg
Subject Zidovudine Small molecule 300 mg